To the Editor:
In the current debate on reference interval(s) for serum thyroid-stimulating hormone (TSH) concentrations, a lowering of the upper reference limit from ϳ4.0 to 2.5, or even 2.0, mU/L has been proposed by the National Academy of Clinical Biochemistry (NABC) (1 ) . This proposal is based in part on the observation that populations with the lowest prevalence of antithyroid antibodies have the lowest TSH upper limits. Other arguments for the lowering of the upper limit of the reference interval are related to the question of whether mild TSH increases have any clinical consequences. This question, however, illustrates the problem of mixing the concepts of (a) decision limits (e.g., discrimination values, cutoffs, action limits), which are based on the clinical consequences and treatment strategies and (b) reference intervals, which are based solely on biology and mathematics applied in an appropriate reference population. This confusion is also addressed in a recent paper on TSH reference interval(s) (2 ) .
The debate for lowering the upper TSH reference limit also includes the argument that the reference distribution for serum TSH should be gaussian in nature, but the upper tail of the distribution is currently skewed by: (a) euthyroid outliers such as may occur in patients recovering from nonthyroidal illness, (b) measurement of bioinactive TSH isoforms, (c) TSH receptor gene polymorphisms, and (d) occult autoimmune thyroid dysfunction. As a consequence, some authorities suggest the distribution tail to be deleted (1 ). In our opinion, however, this upper tail is an essential part of the distribution. In fact, when all values from individuals at risk are removed, log-gaussian distributions are common for most serum components (3 ), as we demonstrated for serum TSH, which is unimodal and log-gaussian (4 ).
We now focus on the newer documentation regarding serum TSH reference intervals and methods. Despite the fact that several publications suggest an upper limit of ϳ4 mU/L, NACB proposes an upper limit of 2.5 mU/L, although only one of several population-based studies supports this ( Table 1) .
As evidenced in Table 1 , studies vary widely in time of sampling and analytical methods used, as well as inclusion and exclusion criteria. The study with the highest relative median serum TSH in the Deutschen Gesellschaft fü r Klinische Chemie und Laboratoriumsmedizin hormone survey could have been expected to demonstrate the highest upper reference limit, but clearly it does not (Table 1) , suggesting that factors other than method standardization play a role. Repeated data from external quality assessment performed from 2000 to 2005 disclose that between-method variation is only a minor source of the variation in serum TSH. The exclusion of individuals at risk, however, has been based on nonstandardized criteria, and the importance of time of sampling has been ignored. In fact, in the majority of publications the time of sampling has not been specified.
There is evidence of a considerable diurnal variation in serum TSH concentration, with a maximum around midnight (6 ) . A decrease of up to 50% occurs from 8:00 to 9:30 AM; thereafter the concentration remains relatively constant until evening, with a smaller nadir in the late afternoon. Because serum TSH concentration decreases markedly during the morning and time of sampling is unknown in most studies, sampling time differences between studies may be a primary reason for the discrepancies in published reference intervals. Individuals working night shifts have displaced or reduced diurnal rhythms, a phenomenon that 
